N-(2-hydroxyethyl)-5-(2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl)pentanamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 生物素及其衍生物
• 英文名称: N-(2-hydroxyethyl)-5-(2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl)pentanamide
• 化学式: C₁₂H₂₁N₃O₃S
• 分子量: 287.38
• InChiKey: UYBGABATOCWMIE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  19
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  116
• 氢给体数：
  4
• 氢受体数：
  4

文献信息

• FLUORESCENT NEAR INFRA-RED (NIR) DYES
  申请人：O'Shea Donal

  公开号：US20120232282A1

  公开（公告）日：2012-09-13

  A compound of formula (I) is described in which each A, which may be the same or different, is a halide selected from fluoride, chloride, bromide and iodide, or is O—Y, wherein Y is a substituted or unsubstituted, saturated or unsaturated, straight or branched chain alkyl moiety. R 1 , R 2 , R 3 , R 6 , R 7 , and R 8 are each independently H, OH, NO 2 or O-L-X, wherein L is a spacer group, and X is a conjugation group or a water-solubilizing group. At least one of R 1 , R 2 , R 3 is OH or O-L-X and at least one of R 6 , R 7 , and R 8 is OH or O-L-X. R 4 and R 5 , which may be the same or different, are each independently H; or are a substituted or unsubstituted, saturated or unsaturated, cyclic moiety; a substituted or unsubstituted, saturated or unsaturated heterocyclic moiety; or a substituted or unsubstituted, saturated or unsaturated, straight or branched chain alkyl moiety. Also described are dye conjugates comprising a compound of the invention.

  公式（I）描述了一种化合物，其中每个A（可以相同也可以不同）是从氟化物、氯化物、溴化物和碘化物中选择的卤素，或者是O—Y，其中Y是取代或未取代的、饱和或不饱和的、直链或支链烷基基团。R1、R2、R3、R6、R7和R8分别独立地是H、OH、NO2或O-L-X，其中L是一个间隔基团，X是一个共轭基团或水溶性基团。R1、R2、R3中至少一个是OH或O-L-X，R6、R7和R8中至少一个是OH或O-L-X。R4和R5（可以相同也可以不同）分别独立地是H；或者是取代或未取代的、饱和或不饱和的、环状基团；取代或未取代的、饱和或不饱和的杂环基团；或者取代或未取代的、饱和或不饱和的、直链或支链烷基基团。还描述了包括本发明化合物的染料共轭物。
• Microbubble-chemotherapeutic agent complex for sonodynamic therapy
  申请人：UNIVERSITY OF ULSTER

  公开号：US11382987B2

  公开（公告）日：2022-07-12

  The invention relates to methods of sonodynamic therapy comprising the co-administration of a microbubble-chemotherapeutic agent complex together with a microbubble-sonosensitiser complex. It further relates to pharmaceutical compositions comprising these complexes and their use in methods of sonodynamic therapy and/or sonodynamic diagnosis. Such methods find particular use in the treatment of cancer, e.g. pancreatic cancer.

  本发明涉及声动力治疗方法，包括同时施用微气泡-化学治疗剂复合物和微气泡-声敏剂复合物。本发明还涉及包含这些复合物的药物组合物及其在声动力治疗和/或声动力诊断方法中的应用。这些方法特别适用于癌症，如胰腺癌的治疗。
• [EN] METHOD FOR CAPTURING MODIFIED NUCLEIC ACID AND APPLICATION THEREOF<br/>[FR] PROCÉDÉ DE CAPTURE D'ACIDE NUCLÉIQUE MODIFIÉ ET SON APPLICATION<br/>[ZH] 一种修饰核酸的捕捉方法及其应用
  申请人：[en]SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES;[zh]中国科学院上海有机化学研究所

  公开号：WO2022257383A1

  公开（公告）日：2022-12-15

  涉及一种修饰核酸的捕捉方法及其应用。具体提供了一种捕获NAD帽修饰的RNA或富集样品中NAD帽修饰的RNA的方法，所述方法包含使式(I)所示化合物与待测样品接触，所述接触在腺苷二磷酸核糖基环化酶存在的条件下进行，所述待测样品包含所述NAD帽修饰的RNA，X-L-B(I)，其中，X代表亲核基团，L代表连接基团，B代表生物素或脱硫生物素，X与B通过L相连。
• PSA CAPTURE AGENTS, COMPOSITIONS, METHODS AND PREPARATION THEREOF
  申请人：Indi Molecular, Inc.

  公开号：US20150093758A1

  公开（公告）日：2015-04-02

  Disclosed herein are novel synthetic prostate specific antigen (PSA)-targeted capture agents that specifically bind PSA. In certain embodiments, these PSA capture agents are biligand or triligand capture agents containing two or three target-binding moieties, respectively.
• SITE SPECIFIC PROTEIN MODIFICATIONS
  申请人：NOVARTIS AG

  公开号：US20170107248A1

  公开（公告）日：2017-04-20

  The present invention relates to method and reagents for use in site-selective modification of protein and peptide. The site selective modification is a selective derivation of the amino functionality at the N-terminus of the protein or the polypeptide using the presence of a neighboring histidine amino acid to increase the reactivity of the N-terminal amino functionality. The modified proteins or peptides obtained by method of the invention may be used for imaging study or therapeutic uses.